Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 2.4x - 2.6x | 2.5x |
| Historical Pb Multiple | -16.9x - 14.2x | 5.9x |
| Fair Value | $0.86 - $0.95 | $0.91 |
| Upside | -14.8% - -5.8% | -10.3% |
| Benchmarks | - | Full Ticker |
| Enliven Therapeutics, Inc. | - | NasdaqGS:ELVN |
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Processa Pharmaceuticals, Inc. | - | NasdaqCM:PCSA |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Anebulo Pharmaceuticals, Inc. | - | NasdaqCM:ANEB |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| ELVN | FFNT.F | PCSA | HRMY | EOLS | ANEB | |||
| NasdaqGS:ELVN | OTCPK:FFNT.F | NasdaqCM:PCSA | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqCM:ANEB | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | 61.4% | NM- | NM- | ||
| Latest Twelve Months | -24.4% | 31.3% | -6.6% | 12.9% | 18.3% | 26.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | NA | -170.4% | NA | -20.1% | -93.5% | NA | ||
| Prior Fiscal Year | NA | -19.8% | NA | 22.1% | -30.5% | NA | ||
| Latest Fiscal Year | NA | -45.9% | NA | 20.4% | -18.9% | NA | ||
| Latest Twelve Months | NA | -46.6% | NA | 20.4% | -18.9% | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -33.9% | -237.0% | -128.9% | 14.7% | -433.2% | -155.4% | ||
| Prior Fiscal Year | -58.2% | -64.9% | -178.5% | 29.6% | -666.9% | -91.4% | ||
| Latest Twelve Months | -32.0% | NM | -354.5% | 25.8% | -1826.1% | -71.5% | ||
| Next Fiscal Year | -51.0% | 82.7% | 273.5% | 30.3% | -66.3% | 1482.9% | ||
| Two Fiscal Years Forward | -177.7% | -190.2% | 80.4% | 29.3% | 186.8% | 138.1% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | NA | 0.1x | NA | 2.3x | 2.6x | NA | ||
| Price / LTM EPS | -10.2x | -0.2x | -0.2x | 11.5x | -13.5x | -5.4x | ||
| Price / Book | 2.9x | -0.1x | 1.1x | 2.5x | 123.1x | 2.8x | ||
| Price / Fwd Book | 4.8x | -0.1x | -0.1x | 1.8x | 320.8x | -8.3x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -0.1x | 2.5x | 123.1x | |||||
| Historical P/B Ratio | -16.9x | 5.9x | 14.2x | |||||
| Selected P/B Multiple | 2.4x | 2.5x | 2.6x | |||||
| (x) Book Value | 15 | 15 | 15 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ELVN | FFNT.F | PCSA | HRMY | EOLS | ANEB | |
| Value of Common Equity | 876 | 8 | 2 | 1,629 | 651 | 41 | |
| (/) Shares Outstanding | 49.0 | 916.4 | 5.3 | 57.3 | 63.6 | 41.1 | |
| Implied Stock Price | 17.87 | 0.01 | 0.29 | 28.40 | 10.24 | 1.01 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 17.87 | 0.01 | 0.29 | 28.40 | 10.24 | 1.01 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |